Lutetium-177 PSMA-I&T

Phase 2Radiopharmaceutical

PPeter MacCallum Cancer Centre, Australia

Lutetium-177 PSMA-I&T is one of 66 small molecule programs targeting Salivary Gland Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Salivary Gland CancerActive, not recruiting

Prostate CancerActive, not recruiting

Salivary Gland CancerPhase 2

Active, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Lutetium-177 PSMA-I&T

PPeter MacCallum Cancer Centre, Australia

Phase 2

1 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Prostate Cancer

NCT05383079

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1/2·NCT05383079·36 enrolled

Salivary Gland Cancer1 trial

Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Completed·RRadboud University Medical Center·Phase 2·NCT04291300·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Lutetium-177 PSMA-I&T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lutetium-177 PSMA-I&T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lutetium-177 PSMA-I&T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peter MacCallum Cancer Centre, Australia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 2[1]
Company: PPeter MacCallum Cancer Centre, Australia

Lutetium-177 PSMA-I&T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Prostate Cancer1 trial

Salivary Gland Cancer1 trial

References

Drug Info

Quick Facts

Related News